Malignant neuroendocrine tumors ICD-10-CM Code range C7A-C7A.8 C78.7
Conditions
Interventions
Group 1: Patients with unresectable liver metastases from a neuroendocrine tumor who received transarterial chemoembolization for local tumor control and symptom relief, particularly in cases of carci
Sponsors
Ruhr Universität Bochum, Johannes Wesling Klinikum Minden, Universitätsinstitut für Radiologie, Neuroradiologie und Nuklearmedizin
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Data analysis of patients who received transarterial chemoembolization between 2023 and 2026 as treatment for liver metastases from neuroendocrine tumors.
Exclusion criteria
Exclusion criteria: Hepatic metastases originating from non-neuroendocrine tumors. Early termination of transarterial chemoembolization treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Symptom control in cases of functional tumor activity 4 weeks after TACE through medical history assessment. Radiological tumor response of the liver metastases during a follow-up examination by CT/MRI after 4 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary resectability Durability of symptom control Progression-free survival Impact on further therapeutic management Safety of the therapy, adverse effects, and complications | — |
Countries
Germany
Contacts
Public ContactNina Haag
Ruhr Universität Bochum, Johannes Wesling Klinikum Minden, Universitätsinstitut für Radiologie, Neuroradiologie und Nuklearmedizin
Outcome results
None listed